{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"An AE was any untoward medical occurrence in clinical study participant temporally associated with use of study intervention, whether or not considered related to study intervention. Dose interruption: for encorafenib = 0 mg dose administered for \\>=1 days; for cetuximab, oxaliplatin, leucovorin, fluorouracil, irinotecan: \\>20 days between successive start dates with non-zero actual doses. Dose reduction: decrease in dose of at least 10%, from the protocol-planned dose and a decrease from the previous non-zero dose; for encorafenib to qualify as a dose reduction, it should have lasted for \\>=2 days. Dose modifications included both dose interruptions and reduction.","reportingStatus":"NOT_POSTED","timeFrame":"Through end of the study","title":"SLI: Number of Participants With Dose Modification of Any Study Intervention Due to AEs","type":"SECONDARY"}